Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 15/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 15/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 15/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18826052 | 0.72 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1BTSHR | |
| SCHEMBL779503 | 0.69 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826070 | 0.69 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL5709449 | 0.68 | SLC6A4 (0.42) | — | |
| SCHEMBL31683943 | 0.65 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826064 | 0.65 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL6881962 | 0.64 | LMNA (0.66) | ADRA2A | |
| SCHEMBL7429847 | 0.64 | LMNA (0.42) | TSHRTDP1 | |
| SCHEMBL11884024 | 0.63 | HDAC9 (0.46) | TSHR | |
| SCHEMBL8310700 | 0.61 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | ADRA2A 138/4885ADRA2B 227/4885ADRA2C 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.